- Home
- SHOT vs SCYX Comparison
SHOT vs SCYX Comparison
Compare SHOT & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SHOT
- SCYX
- Stock Information
- Founded
- SHOT 2018
- SCYX 1999
- Country
- SHOT United States
- SCYX United States
- Employees
- SHOT N/A
- SCYX N/A
- Industry
- SHOT Biotechnology: Pharmaceutical Preparations
- SCYX Biotechnology: Pharmaceutical Preparations
- Sector
- SHOT Health Care
- SCYX Health Care
- Exchange
- SHOT Nasdaq
- SCYX Nasdaq
- Market Cap
- SHOT 30.4M
- SCYX 28.5M
- IPO Year
- SHOT 2020
- SCYX 2014
- Fundamental
- Price
- SHOT $0.73
- SCYX $0.70
- Analyst Decision
- SHOT
- SCYX
- Analyst Count
- SHOT 0
- SCYX 0
- Target Price
- SHOT N/A
- SCYX N/A
- AVG Volume (30 Days)
- SHOT 7.4M
- SCYX 187.5K
- Earning Date
- SHOT 08-13-2025
- SCYX 08-11-2025
- Dividend Yield
- SHOT N/A
- SCYX N/A
- EPS Growth
- SHOT N/A
- SCYX N/A
- EPS
- SHOT N/A
- SCYX N/A
- Revenue
- SHOT $573,336.00
- SCYX $2,630,000.00
- Revenue This Year
- SHOT N/A
- SCYX $410.22
- Revenue Next Year
- SHOT N/A
- SCYX $248.83
- P/E Ratio
- SHOT N/A
- SCYX N/A
- Revenue Growth
- SHOT 69.32
- SCYX N/A
- 52 Week Low
- SHOT $0.23
- SCYX $0.66
- 52 Week High
- SHOT $1.77
- SCYX $2.21
- Technical
- Relative Strength Index (RSI)
- SHOT 60.31
- SCYX 41.70
- Support Level
- SHOT $0.66
- SCYX $0.67
- Resistance Level
- SHOT $1.13
- SCYX $0.74
- Average True Range (ATR)
- SHOT 0.16
- SCYX 0.04
- MACD
- SHOT 0.01
- SCYX 0.00
- Stochastic Oscillator
- SHOT 45.27
- SCYX 10.15
About SHOT Safety Shot Inc.
Safety Shot Inc is a wellness and functional beverage company. It is set to launch Safety Shot, the patented beverage that helps people feel faster by reducing blood alcohol content and boosting clarity.
About SCYX SCYNEXIS Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.